AusTrials is pleased to have been involved in conducting the ARISE-HF Phase 3 trial which has since announced encouraging results. Applied Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, has announced the topline results of the ARISE-HF Phase 3…
This paper, co-authored by Associate Professor Roy Rasalam (Principal Investigator at AusTrials Sunshine in Melbourne), systematically reviews randomized controlled trials assessing effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) on hospitalization for heart failure (HHF) and cardiac structure/function and explore randomized controlled trial (RCT)-derived evidence for SGLT2i efficacy mechanisms in heart failure (HF). This review found…
Diabetes mellitus (DM) is an increasingly common, yet complex and chronic metabolic illness that requires ongoing medical care. Type 2 DM (T2DM) is the most common form of DM, resulting from an interaction of genetic, environmental, and behavioural factors. Within 20 years, the number of people in Australia with T2DM may increase from an estimated 870,000 in 2014, to more than 2.5 million. People with diabetes…
